Purpose of Review <p>Cytomegalovirus (CMV) is the most common congenital infection and a major cause of neurodevelopmental delay, but most cases are missed without universal screening. This review summarizes the status of newborn CMV screening, as well as related challenges and outstanding questions.</p> Recent Findings <p>Universal newborn CMV screening programs are increasingly common and benefit large numbers of infected infants missed by clinical suspicion or risk-based screening. Universal newborn CMV screening requires substantial investment but has demonstrated benefits and is predicted to be cost-effective. While CMV PCR of oral swabs confirmed by urine testing is the gold standard for diagnosis in newborns, these samples are not currently routinely obtained. Thus, dried blood spots, which are already universally collected at birth, have been used by most programs, despite the limited sensitivity of this approach.</p> Summary <p>&#xa0;Universal newborn CMV screening has proven to be feasible and beneficial, and additional improvements are possible.</p>